| Drug General Information |
| Drug ID |
D0BB1X
|
| Former ID |
DIB016830
|
| Drug Name |
KRP-105
|
| Indication |
Lipid metabolism disorder [ICD10:E75-E78]
|
Terminated |
[1]
|
|---|
| Company |
Kyorin Pharmaceutical Co Ltd
|
| Target and Pathway |
| Target(s) |
Peroxisome proliferator activated receptor alpha |
Target Info |
Agonist |
[2]
|
|---|
|
KEGG Pathway
|
PPAR signaling pathway
|
|
cAMP signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Glucagon signaling pathway
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Hepatitis C
|
|
Pathway Interaction Database
|
RXR and RAR heterodimerization with other nuclear receptor
|
|
Reactome
|
RORA activates gene expression
|
|
BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
|
PPARA activates gene expression
|
|
YAP1- and WWTR1 (TAZ)-stimulated gene expression
|
|
Transcriptional activation of mitochondrial biogenesis
|
|
Activation of gene expression by SREBF (SREBP)
|
|
Transcriptional regulation of white adipocyte differentiation
|
|
Nuclear Receptor transcription pathway
|
|
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Circadian Clock
|
|
WikiPathways
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Nuclear Receptors Meta-Pathway
|
|
Estrogen Receptor Pathway
|
|
PPAR Alpha Pathway
|
|
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
YAP1- and WWTR1 (TAZ)-stimulated gene expression
|
|
Activation of Gene Expression by SREBP (SREBF)
|
|
Adipogenesis
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
Circadian Clock
|
|
Nuclear Receptors
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026674) |
|---|
| REF 2 | Discovery of cyclic amine-substituted benzoic acids as PPARalpha agonists. Bioorg Med Chem Lett. 2012 Jan 1;22(1):334-8. |
|---|
